Troglitazone in type II diabetes mellitus

Pharmacotherapy

Volumn 18, Issue 3, 1998, Pages 539-548

  Sparano, Nicole ^a,b   Seaton, Terry L ^c  

^a WILKES UNIVERSITY   (United States)

^b Wyoming Valley Family Practice Residency   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; COLESTYRAMINE; CONTRACEPTIVE AGENT; FEXOFENADINE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; TERFENADINE; TROGLITAZONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; GASTROINTESTINAL DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL;

CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; RANDOMIZED CONTROLLED TRIALS; THIAZOLES; THIAZOLIDINEDIONES; UNITED STATES;

EID: 0031960061     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cowie CC Eberhardt MS, eds. Diabetes 1996 vital statistics. Alexandria, VA: American Diabetes Association, 1996.
2. Dagogo-Jack S, Santiago JV. Pathophysiology of type II diabetes and modes of action of therapeutic interventions. Arch Intern Med 1997;157:1802-17.
3. Suter S, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15(2):193-203.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;14:977-86.
5. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study 17: a 9-year update of a randomized controlled trial on the effect of improved metabolic control on complications in non-insulin dependent diabetes mellitus. Ann Intern Med 1996;124:136-45.
6. Mediratta S, Fozailoff A, Frishman W. Insulin resistance in systemic hypertension: pharmacologic implications. J Clin Pharmacol 1995;35:943-56.
7. Koivisto VA. Insulin therapy in type II diabetes. Diabetes Care 1993;16(suppl 3):29-39.
8. Stamler J, Pick R, Katz LN. Effect of insulin in the induction and regression of atherosclerosis in the chick. Circ Res 1960;8:572-5.
9. Cruz AB, Amatuzio D, Grande F, Hay J. Effect of intra-arterial insulin on tissue cholesterol and fatty acids in alloxan-diabetic dogs. Circ Res 1961;9:39-42.
10. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
11. American Diabetes Association. The pharmacologic treatment of hyperglycemia in NIDDM. Diabetes Care 1995;11:1510-18.
12. Ferrara A, Barrett-Coner EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo study. Am J Epidemilol 1994;10:857-69.
13. Umeda F. Potential role of thiazolidinediones in older diabetic patients. Drugs 1995;7(5):331-7.
14. Lee AJ. Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 1996;16(3):327-51.
15. Mooradian AD. Drug therapy of non-insulin dependent diabetes mellitus in the elderly. Drugs 1996;51(6):931-41.
16. Petrie JR, Donnell R. New pharmacological approaches to insulin and lipid metabolism. Drugs 1994;47(5):701-10.
17. Iwamoto Y, Kuzuya T, Matsuda A, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991;14(11): 1083-6.
18. Kuzuya T, Iwamoto Y, Kosaka K, et al. A pilot trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1991;11:147-54.
19. Parke-Davis. Rezulin (troglitazone) package insert. Morris Plains, NJ; 1997.
20. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
21. Park KS, Carter LA, Mudaliar S, Nikoulina S, Henry R. Troglitazone effects on gene expression in human skeletal muscle involve regulation of PPAR gamma. Diabetes 1997;46(suppl 1):85A.
22. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-20.
23. Parke-Davis. Data on file. Morris Plains, NJ; 1997.
24. Mimura K, Umeda F, Hiramatsu S, et al. Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type II diabetes. Diabet Med 1994;11: 685-91.
25. National Diabetes Data Group. Diabetes in America, 2nd ed. Bethesda, MD: National Institutes of Health, 1995.
26. Onuma T, Tsutsui M, Goto T, Boku A, Takebe AK. The effects of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in nonobese Japanese patients with non-insulin dependent diabetes mellitus: a pilot study. Curr Ther Res 1994;55:416-21.
27. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone, a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19(2):151-6.
28. Ghazzi M, Radke-Mitchell L, Venable T, et al. Troglitazone improves glycemic control in patients with type II diabetes who are not optimally controlled on sulfonylurea. Diabetes 1997;46(suppl 1):169A.
29. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effect of combination therapy of troglitazone and sulfonylureas in patients with type II diabetes who were poorly controlled by sulfonylurea therapy alone. Diabet Med 1996;13:365-70.
30. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. New Engl J med 1998;338:861-6.
31. Antonucci T, Whitcomb R, McLain R, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997;20:188-93.
32. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
33. Kumar S, Boulton JM, Beck-Nielsen H, et al. Troglitazone, an insulin enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996;39:701-9.
34. Stephens TW, Bergman A, Bue-Valleskey JM, et al. Thiazolidinedione induced cardiac biochemical changes and increased IgF-1 action on cardiomyocytes. Clin Res 1994;42:773A.
35. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997;46:433-9.
36. Cardinale V. Red book. Montvale, NJ: Medical Economics Data, 1997.
37. Hermann LS, Schersten B, Bitzen P, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea alone and in various combinations. Diabetes Care 1994;17:1100-9.
38. Fujimoto WT, and the Diabetes Prevention Program Research Group. A national multicenter study to learn whether type II diabetes can be prevented: the diabetes prevention program. Clin Diabet 1997;Jan/Feb:13-16.